Engineered immune cells take on lupus and other autoimmune diseases

NCT ID NCT07507201

Recruiting now Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participants to evaluate safety and early signs of effectiveness. Participants receive a single infusion after a conditioning regimen and are monitored for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: universal allogeneic CAR-T cells targeting CD19 and BCMA
What this could lead to: If successful, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 15 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED SYSTEMIC VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis autoimmune disease granulomatosis with polyangiitis idiopathic multidrug-resistant nephrotic syndrome IgA glomerulonephritis nephrotic syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA ASSOCIATED SYSTEMIC VASCULITIS AUTOIMMUNE DISEASES IGA NEPHROPATHY (IGAN) MULTI-DRUG RESISTANT NEPHROTIC SYNDROME SYSTEMIC LUPUS ERTHEMATOSUS (SLE) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Locations

Children's Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.